AbbVie (ABBV) and Remegen announce exclusive licensing agreement to develop a novel bispecific antibody for advanced solid tumours

AbbVie's exclusive licensing agreement with RemeGen marks a significant strategic move in the biotech space, equipping AbbVie with rights to a potentially lucrative bispecific antibody.

Newsquawk StaffPublished On the live feed at 1 more headline followed before this page went public
Newsquawk headlinesUTC

Around six borrowers are looking to sell US IG bonds on Monday, according to a Bloomberg survey

NEC Director Hassett says respect independence of the Fed; Fed building renovation has dramatic cost overruns; plans look inconsistent with testimony, via CNBC

AbbVie (ABBV) and Remegen announce exclusive licensing agreement to develop a novel bispecific antibody for advanced solid tumours

EU Commissioner says it would be the end of NATO if the US took Greenland by force

Newsquawk Daily US Conference Calendar - 12th January 2026: BMY, JNJ, BA, MCK, MSI, NKE, NOC

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize RC148 outside of the Greater China territory.
  • RemeGen will receive an upfront payment of USD USD 650mln and is eligible to receive up to USD 4.95bln in aggregate development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales outside the Greater China territory.
Context

The substantial upfront payment and future milestone structures suggest strong confidence in the drug's market potential, likely positioning AbbVie favorably against peers in the advanced solid tumors treatment arena. This deal could bolster AbbVie's growth trajectory, reflecting positively on its stock and related biotech equities.

Related headlines

The whole workspace, free to try.

Try it free